PIK3CA mutations predict resistance to trastuzumab/pertuzumab and nab-paclitaxel in primary HER2-positive breast cancer - Massive parallel sequencing analysis of 293 pretherapeutic core biopsies of the GeparSepto study

被引：0
|
作者：
Loibl, S.
Budczies, J.
Weichert, W.
Furlanetto, J.
Stenzinger, A.
Pfarr, N.
von Minckwitz, G.
Jackisch, C.
Schneeweiss, A.
Fasching, P.
Schmatloch, S.
Aktas, B.
Nekljudova, V.
Weber, K.
Untch, M.
Denkert, C.
机构：
[1] German Breast Grp, Neu Isenburg, Germany
[2] Charite, Berlin, Germany
[3] Univ Hosp Heidleberg, Heidelberg, Germany
[4] Sana Klinikum Offenbach, Offenbach, Germany
[5] Univ Hosp Erlangen, Erlangen, Germany
[6] Elisabeth Krankenhaus Kassel, Kassel, Germany
[7] Univ Hosp Sen, Essen, Germany
[8] Helios Kliniken Berlin Buch, Berlin, Germany
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P3-07-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-07-03
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Predictive impact of absolute lymphocyte counts for progression-free survival in HER2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
    Araki, Kazuhiro
    Ito, Yoshinori
    Fukada, Ippei
    Kobayashi, Kokoro
    Ohno, Shinji
    Miyagawa, Yoshimasa
    Imamura, Michiko
    Kira, Ayako
    Takatsuka, Yuichi
    Egawa, Chiyomi
    Suwa, Hirofumi
    Miyoshi, Yasuo
    CANCER RESEARCH, 2018, 78 (04)
  • [22] Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study.
    Chen, Xiaosong
    Huang, Jiahui
    Tong, Yiwei
    Ren, Weili
    Yu, Jing
    Gao, Weiqi
    Zhu, Siji
    Hong, Jin
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy
    Fontana, Andrea
    Allegrini, Giacomo
    al Zoubi, Mazhar
    Collecchi, Paola
    Mazzanti, Chiara
    Stasi, Irene
    Lucchesi, Sara
    Bona, Eleonora
    Ferrarini, Ilaria
    Salvadori, Barbara
    Arrighi, Giada
    Marcucci, Lorenzo
    Filidei, Mario
    Orlandini, Cinzia
    Falcone, Alfredo
    Bevilacqua, Generoso
    Zavaglia, Katia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] IMPACT OF PIK3CA MUTATIONS AND P95HER2 EXPRESSION ON THE OUTCOME OF HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS TREATED WITH A TRASTUZUMAB-BASED THERAPY
    Stasi, I.
    Fontana, A.
    Allegrini, G.
    Mazzanti, C.
    Lucchesi, S.
    Bona, E.
    Ferrarini, I.
    Salvadori, B.
    Falcone, A.
    Zavaglia, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [25] Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)
    Nishimura, Reiki
    Arima, Nobuyuki
    Toyoshima, Satoshi
    Ohi, Yasuyo
    Anan, Keisei
    Sagara, Yasuaki
    Mitsuyama, Shoshu
    Tamura, Kazuo
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (01) : 47 - 52
  • [26] An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer
    Sueta, Aiko
    Yamamoto, Yutaka
    Yamamoto-Ibusuki, Mutsuko
    Hayashi, Mitsuhiro
    Takeshita, Takashi
    Yamamoto, Satoko
    Iwase, Hirotaka
    PLOS ONE, 2014, 9 (12):
  • [27] Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status
    Irelli, Azzurra
    Parisi, Alessandro
    D'Orazio, Carla
    Sidoni, Tina
    Rotondaro, Silvia
    Patruno, Leonardo
    Pavese, Francesco
    Bafile, Alberto
    Resta, Valter
    Pizzorno, Laura
    Ciuffetelli, Virginia
    Dal Mas, Antonella
    Calvisi, Giuseppe
    Di Sibio, Alessandra
    Marzullo, Anna
    Zelli, Veronica
    Compagnoni, Chiara
    Tessitore, Alessandra
    Alesse, Edoardo
    Ficorella, Corrado
    Cortellini, Alessio
    Cannita, Katia
    CANCERS, 2022, 14 (12)
  • [28] Analysis of PIK3CA mutation abundance in primary breast cancer with droplet digital PCR identifies frequent sub-clonal PIK3CA mutations in ER negative and/or HER2 positive breast cancer
    Garcia-Murillas, I.
    Pearson, A.
    Lambros, M.
    Natrajan, R.
    Segal, C.
    Dowsett, M.
    Turner, N. C.
    CANCER RESEARCH, 2013, 73
  • [29] PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
    Loibl, S.
    Majewski, I.
    Guarneri, V.
    Nekljudova, V.
    Holmes, E.
    Bria, E.
    Denkert, C.
    Schem, C.
    Sotiriou, C.
    Loi, S.
    Untch, M.
    Conte, P.
    Bernards, R.
    Piccart, M.
    von Minckwitz, G.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1519 - 1525
  • [30] Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models
    Bose, Sreyashree
    Mistry, Ragini
    Liu, Chia Chia
    Nanda, Sarmistha
    Qin, Lanfang
    Selenica, Pier
    Gazzo, Andrea
    Zhu, Yingjie
    Mancini, Michael A.
    Stossi, Fabio
    Diala, Irmina
    Eli, Lisa D.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    Veeraraghavan, Jamunarani
    CANCER RESEARCH, 2022, 82 (04)
12345